anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A Pickering Emulsion Comprising Nano Crystals of Silybin and A Method of Preparation Thereof The present invention discloses a Pickering emulsion comprising nano crystals of silybin and a method of preparation thereof, wherein the emulsion is an oil-in-water type Pickering emulsion comprising nano crystals of silybin, oil phase and water. The preparation method of Pickering emulsion disclosed in the present invention makes silybin into nano crystals through high-pressure homogenization. The nano crystals of silybin are adsorbed to the surface of oil droplets to make the oil droplets wrapped by silybin. Silybin is partially dissolved in the oil phase, and partially adsorbed to the surface of the oil droplets in the form of nano crystals. The oil droplets can be stably dispersed in water to form stable emulsion. Silybin in the emulsion is active ingredient and also plays a role in stabilizing the emulsion. The emulsion prepared by this method does not contain any surfactant or organic solvents. It has good stability, rapid release rate and sound bioavailability. FIGURE FOR A, &lt;DocRef#00123529-CX &gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide measures for preventing the formation of an offensive odor derived from a very small amount of impurities of an ester of oleic acid with glycerol or polyglycerol or an offensive odor caused by storing a skin care preparation for external use containing the ester of the oleic acid with the glycerol or the polyglycerol.  &lt;P&gt;SOLUTION: This skin care preparation for external use contains (1) one, two, or more kinds selected from the esters of the oleic acid with the glycerol or the polyglycerol and (2) anethole. It is preferable that diglycerol tetraoleate is used as the ester of the oleic acid with the glycerol or the polyglycerol. Further, it is preferable that fat and oil existing in a liquid state at 1 atm and 25°C is contained in the preparation in an amount of 40-80 mass% based on the total amount of the skin care preparation for external use. Furthermore, it is preferable that 10-70 mass% of the fat and oil existing in the liquid state at 1 atm and 25°C comprises the diglycerol tetraoleate.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:The titled composition, obtained by dispersing acetaminophen or a pharmaceutical containing the acetaminophen in macrogol and/or propylene glycol, and having fluidity suitable for filling. CONSTITUTION:A composition for filling soft capsules obtained by dispersing &lt;1.5pts.wt., preferably 0.7-1.4pts.wt. acetaminophen or a pharmaceutical containing the acetaminophen, e.g. an antitussive and expectorant such as hydrobromic acid, an antihistaminic agent such as chlorpheniramine or vitaminic agent, in the form of a prepared fine powder in 1pts.wt. macrogol and/or propylene glycol or incorporating both and finely dividing both therein, and dispersing both therein. EFFECT:The acetaminophen can be uniformly dispersed with the specific water- soluble base even in a small amount thereof, and the composition has fluidity suitable for filling.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition and a method for modulating an interaction between a dendritic cell and T-cell.  &lt;P&gt;SOLUTION: A compound that binds to a C-type lectin on the surface of a dendritic cell is used for preparing a composition for modulating, in particular reducing, an immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interaction between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM (intercellular adhesion molecule) receptor on the surface of a T-cell. The composition can be used for preventing/inhibiting an immune response to a specific antigen, for immunotherapy, for immunosuppression, for treating auto-immune diseases, for treating allergy and/or for inhibiting HIV infection. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, a plant lectin, an antibiotic, a sugar, a protein or an antibody against C-type lectin. Such the antibody and a method for isolating dendritic cells using the same are also provided.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE: To obtain a therapeutic agent for myocardial reperfusion injury and myocardial stunning containing 3-substituted-2-oxyindole-1-carboxamide derivative. CONSTITUTION: This therapeutic agent contains a compound of formula I (X is H, F, Cl, Br, an alkyl, an alkoxy, CF3 , phenyl, etc.; Y is H, F, Cl, Br, an alkyl, an alkoxy, CF3 , etc.; X, Y and an adjacent C foam a group of formula II, etc.; R&lt;1&gt; is an alkyl, a cycloalkenyl, phenyl, etc.), a salt thereof or a solvate thereof as an active ingredient. The treatment and prevention of ischemia induced myocardial injury or cytokine mediated myocardial injury is carried out by administering a daily dose of 1 mg-1.5 g, preferably 1-300 mg of the therapeutic agent by dividing to one to several portions. The compound of formula I is exemplified by 5-chloro-3-(2-thenoyl)-2-oxyindole-1-carboxamide.
PURPOSE:To improve water resistance, heat resistance, scratch resistance, adhesive resistance and swelling resistance by incorporating a specified activating reagent in an alkali-treated gelatin to activate carboxyl groups of side chains of gelatin and amidating it with a nucleophilic reagent. CONSTITUTION:An alkali-treated gelatin is incorporated with 5-20wt.% at least one compd. selected from carbodiimide reagents and salts thereof of the formula (wherein R is ethyl, cyclohexyl or benzyl; R&#39; is dimethylaminopropyl, cyclohexyl or morpholinoethyl) to activate carboxyl groups of the side chains of gelatin. Then, 0.1-10wt.% said gelatin is incorporated in an aq. soln. contg. 0.5-6mol of a nucleophilic reagent (e.g. NH4Cl) and the mixture is reacted at a pH of 3.0-6.5, at 30-70 deg.C for 1-12hr and the activated carboxyl groups are amidated to obtain an improved alkali-treated gelatin wherein an iso-ionic point is at a pH of 7-10.5.
This disclosure relates to the development of nucleotide compositions directed to spliced gene variants that generate circular RNAs that are indicative of Alzheimer&#39;s disease. In some aspects, the nucleotides are siRNA compositions. In some aspects, the circular RNA is from a backspliced variant produced from the MAPT gene. The circular RNAs contain multiple microtubule binding domains and feature no frame shift and no stop codon when translated, allowing for consistent production. The siRNA compositions disclosed herein demonstrate good efficacy at silencing expression of the circRNAs. Circular RNAs, including tau circular RNAs exhibit a dramatic increase in translation after undergoing A&gt;I editing, i.e. deamination of adenosines to inosines, which causes the formation and accumulation of pathological proteins. This accumulation can be prevented by siRNAs. In addition, five circular RNAs have been identified that correlate in expression levels with Alzheimer&#39;s disease severity. These circRNAs express proteins after adenosine to inosine editing. Part of these circproteins are specific for circular RNAs and could be molecular markers for Alzheimer&#39;s disease, accessible from cerebrospinal fluid.
The invention relates to a Chinese medicinal composition for relieving drug addition, which is composed of cathartic, vomiting-causing, tonifying and regulating materials. The cathartic materials consist of Rhubarb, Croton Seed (prepared) and Licorice Root. The vomiting-causing materials consist of Muskmelon Base and Licorice Root. The tonifying materials consist of middle-strengthening and qi-benefiting decoction, decoction of eight ingredients, and Spine Date Seed, Chicken Gizzard Skin, Cassia Bark and gardenia. By accurately applying the principle of syndrome-differentiation treatment, the cathartic and vomiting-causing materials can remove toxic materials in human body, the regulating materials can eliminate residual toxins in bowls and stomach, and the tonic materials can invigorate the spleen and stomach and qi and blood. Under the doctor&#39;s instruction, the composition can eliminate drug addition completely in days.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a combination of amphipatic substances forming aggregate suspensions in a polar liquid.  &lt;P&gt;SOLUTION: Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures the aggregates to have extended, unusually adaptable surfaces. This is due to simultaneous action on the aggregates of at least two soluble substances amongst three system components, at least one of which is an active ingredient and preferably a drug; the third component, alternatively, can take the role of a drug. The application further deals with the use of the combinations in pharmaceutical preparations transporting drugs into the body of warm blood creatures. This is made possible by the drug loading capability of the aggregates with the highly flexible and deformable coating, which renders the resulting drug carriers highly adaptable. The application finally reveals suitable methods for manufacturing and usage of the carriers.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a non-swelling mica powdery material without having creaking or rough feeling, having a good sliding property and a very good use feeling.  &lt;P&gt;SOLUTION: The surface-treated non-swelling synthetic mica powdery material is characterized by surface-treating a non-swelling synthetic mica powder material with an ammonium cationic surfactant, and having ≤0.25 dynamic frictional coefficient and ≥120° contact angle with water. After heat-treating the non-swelling synthetic mica powdery material at 600-1,350°C, the surface-treated material is obtained by bringing the material into contact with the ammonium cationic surfactant in an aqueous solvent. By heat-treating before the surface-treatment, the non-swelling synthetic mica powdery material having a very high water repellency and use feeling is obtained. By using the ammonium cationic surfactant and a higher fatty acid together, the water repellency and use feeling are further improved. It is suitable to use 0.1-5 mass% ammonium cationic surfactant and 0.1-5 mass% higher fatty acid.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a calorie-restricting food capable of preventing, treating and/or improving diabetes mellitus and obesity.  &lt;P&gt;SOLUTION: The calorie-restricting food comprises an inhibitor having inhibiting activity against α-glucosidase as an active ingredient. The inhibitor includes an antagonism inhibitor and a non-antagonism inhibitor. The antagonism inhibitor is preferably Salacia extract obtained by extracting root and/or stem of Salacia reticulata of the family Hippocrateaceae or the family Celastraceae with a solvent. The non-antagonism inhibitor is preferably Coleus extract obtained by extracting a root of Coleus froskohlii which is a plant of the family Labiatae with a solvent.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A system and method of establishing instant communication session with health providers starts with processor receiving request from member-related client device and generating, using a topic model engine, keywords based on reported information associated with user of the member-related client device and historical provider information associated with user. Processor generates risk scores using predictive models associated with conditions and identifies specialists based on the keywords and the risk scores. Processor selects a subset of the specialists based on a user&#39;s preferences associated with gender, age, or language and identifies a specialist match based on a highest satisfaction score or a lowest contractual rate. The specialist match is a specialist included in the subset. Processor establishes a communication session between the member-related client device and a provider client device associated with the specialist match. Other embodiments are disclosed herein.
&lt;P&gt;PROBLEM TO BE SOLVED: To attain good quality mineral-rich caulerpa lentillifera soaps free from fibers or scum, the soaps also containing an ingredient of Anredera cordifolia which has been noted recently.  &lt;P&gt;SOLUTION: The caulerpa lentillifera soaps are produced by drying not only marketable caulerpa lentillifera but also residual caulerpa lentillifera after being sorted, and souvenirs of caulerpa lentillifera which have being remaining unsold, and waste caulerpa lentillifera which was used once as dishes in cafeterias or Japanese style restraints, and using the dried caulerpa lentillifera as raw materials of soaps. It is an excellent idea to effectively use caulerpa lentillifera which has high market values and to effectively use resources. Even caulerpa lentillifera having few branched bunch of grains and many straight stems which are not suitable as commercial products are not discarded but can thus be used effectively. Moreover, the soaps also contain an Anredera cordifolia extract including minerals which are different in kind from caulerpa lentillifera. Then, mineral-rich soaps having a high mineral content, containing a slimy component which is unique to Anredera cordifolia and being gentle to the skin are produced.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention pertains to the bio-pharmaceutical field and relates to a medicine combination for treating tumor. The tumor is the worldwide No. 2 killer of human being and the drug resistance is one of the difficulties in the treatment of the tumor diseases. Therefore, to find a chemical compound which can reduce drug resistance is one of the hot topics in the study field of tumor disease. The invention provides the medicine combination for treating tumor and the medicine combination comprises nucleic acid with a gene sequence of 5&#39;-GCCAGUGGAGGCUUCCAGG-3&#39; or 5&#39;-GCCAGTGGAGGCTTCCAGG-3&#39; and daunomycin. The application of the nucleic acid and the daunomycin can dramatically reduce the drug resistance of tumor cells.
Agents for blocking T cell-mediated immune reactions are provided. Such agents are peptides, referred to hereinafter as &#34;CD28 peptide mimetics&#34;, of from 15 to 30 amino acids in length. The CD28 peptide mimetics comprise the hexapeptide motif &#39;MYPPPY&#39; or a retro-inverso isomer thereof. The CD 28 peptide mimetics further comprise flanking sequence at the amino and carboxyl terminus of the hexapeptide motif. Such flanking sequence permit the CD28 peptide mimetic to assume a polyproline II (PPII) conformation when placed in water or a buffered solution at physiological pH and a temperature of about 25  DEG C. Methods for treating subjects with T cell mediated autoimmune diseases or disorders are also provided Such methods comprise administering one or more of the CD 28 peptide mimetics to a subject which has such disease or disorder. 30. The present invention also relates to a method of blocking activation and proliferation of CD4+ cells. The method comprises contacting such cells with one or more of the present CD 28 peptide mimetics.
<b><br>Introduction:</b> The COMQ-12 questionnaire is a tool to assess the quality of life in patients with chronic otitis media in many countries. The questionnaire consists of 12 questions: seven relating to the severity of symptoms, two regarding the impact of the disease on lifestyle and work, two concerning the impact on the need for healthcare, and one is a general question. Each question is rated on a scale from 0 to 5.</br> <b><br>Aim:</b> To present the validation process and the final version of the Polish version of the COMQ-12 questionnaire.</br> <b><br>Material and methods:</b> The Polish version of the COMQ-12 questionnaire was prepared based on an independent translation of the English version by three physicians (two otolaryngology specialists and one physician in the process of specialization in otolaryngology). The questionnaire was validated in a study including 60 participants: 30 patients with chronic otitis media and 30 volunteers without a history of middle ear diseases or hearing disorders. Each participant was asked to complete the COMQ-12 questionnaire twice at an interval of 4 weeks apart. The internal consistency, reliability, and construct validity of the questionnaire were analyzed using Cronbach's alpha and McDonald's omega coefficients, Spearman's rho correlation coefficient, and the Mann-Whitney test, respectively.</br> <b><br>Results:</b> High internal consistency, reliability, and construct validity of the Polish version of the COMQ-12 questionnaire were shown in the course of statistical analysis. The overall internal consistency was 0.95 and 0.97 as assessed by Cronbach's alpha and McDonald's omega coefficients, respectively. Spearman's rho correlation coefficient was above 0.89 for each question. Statistically significant differences in the COMQ-12 total scores were obtained between patients with chronic otitis media and the control group.</br> <b><br>Conclusions:</b> The Polish version of the COMQ-12 questionnaire can be a valuable clinical tool for the assessment of the quality of life in patients suffering from chronic otitis media.</br&gt.
Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a DNA sequence which is expressed by the cell and which codes for a protein having complement inhibitory activity and which provides protection against complement-based lysis, i.e. hyperacute rejection. In addition, the cell&#39;s natural genome is changed so that proteins encoded by the class I or class II major histocompatability complex genes do not appear on the cell&#39;s surface. In this way, attack by T-cells is avoided. Optionally the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.
&lt;P&gt;PROBLEM TO BE SOLVED: To make setting work easy as to display disposition of an image, and to reflect preference of an observer.  &lt;P&gt;SOLUTION: This medical image display device displays a medical image and other medical data on a display part. An image storage part to store the medical image and a processing means are connected to the display part. A frequency storage part and a mode storage part are connected to the processing means, and when the medical image is displayed, the frequency storage part stores frequency of disposition of different kinds. The medical image display device automatically sets the display disposition of the medical image based on the frequency of the disposition of different kinds. A kind of disposition used highly frequently has high possibility that preference of a diagnostic reader is reflected, and if the kind of disposition is used as it is or with a slight modification, setting work relating to the display disposition is easy.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
1364672 Penicillin esters and bromophthalide BEECHAM GROUP Ltd 23 June 1972 [9 June 1971] 19604/71 Headings C2A and C2C The novel phthalidyl ester of 6 - [D(-) - α- aminophenylacetamido] penicillanic acid of Formula I: and pharmaceutically acceptable acid addition salts thereof, e.g. salts with hydrochloric acid and 3 - (2&lt;SP&gt;1&lt;/SP&gt; - chloro - 6&lt;SP&gt;1&lt;/SP&gt; - fluorophenyl) - 5 - methyl- 4-isoxazolyl - penicillin, may be prepared (1) by reacting 6-aminopenicillanic acid phthalide ester or a silyl derivative thereof with a reactive N-acylating derivative of the (-) isomer of a compound of Formula II: wherein X is an amino group, a protected amino group or a group which is convertible to an amino group, removing the silyl group, if present, by hydrolysis or alcoholysis, and if X is not an amino group, converting it to such a group under neutral or acid conditions or (2) by reacting a compound of Formula V: or a reactive esterifying derivative thereof, in which X is as above defined, with a compound of Formula VI: or a reactive esterifying derivative thereof, and, if X is not an amino group, subsequently converting it to an amino group under neutral or acid conditions. The novel 6-aminopenicillanic acid phthalidyl ester may be prepared by coupling 6-aminopenicillanic acid with 3-bromophthalide or by coupling an N-protected derivative of 6-aminopenicillanic acid with 3-bromophthalide and thereafter removing the protecting group. The phthalidyl esters of 6-[D(-)α-aminophenylacetamido] penicillanic acid having an N- protected amino group or a group convertible to an amino group are also stated to be novel. 3-Bromo-phthalide is prepared by reacting phthalide with N-bromosuccinimide. Pharmaceutical compositions comprise the phthalidyl ester of 6-[D(-)α-aminophenylacetamido] penicillanic acid or a pharmaceutically acceptable acid addition salt thereof and a carrier. The compositions may be administered orally in the form of powders, syrups, tablets, capsules or pills.
The invention relates to application of a chloride ion channel inhibitor lanjiquinone in an anti-diarrhea drug. Intestinal canal Cl ‑ The channel is used as a key channel for intestinal fluid secretion and becomes a potential diarrhea treatment target. The invention relates to Lanceoquinone p-intestinal Cl ‑ Discovery of channel inhibitory activity, particularly therapeutic effects of oral lanugo quinone on bacterial and viral induced diarrhea. Studies have shown that lanugenon reversibly inhibits TMEM16A channel activity against CaCC and CFTR Cl ‑ The channels also have an inhibitory effect. The gavage lanuginose can reduce intestinal juice secretion induced by STa and CT, and obviously improve diarrhea symptoms induced by cholera toxin and rotavirus. In addition, intestinal motility studies have shown thatThe snow quinone can obviously slow down intestinal peristalsis and inhibit contraction of intestinal smooth muscle, but has no obvious influence on contraction frequency. The lanugenone can be applied to medicines for treating cholera, traveler&#39;s diarrhea and rotavirus diarrhea, develops new pharmacological activity of the lanugenone, and provides a new choice for research and development of anti-diarrhea medicines.
PROBLEM TO BE SOLVED: To manage the relation between the unchanged information and the changed information and also to display the unchanged information as necessary by holding the medical information display information having its unchanged contents and performing the display based on the display information. SOLUTION: A medical information management file 31 manages the display information on the medical information on every patient who is managed by an electronic patient&#39;s record device and produces a file per patient. A display information file 32 is shown in a display information file name included in the file 31. Thereby the file 32 also produces a file per patient. A changed information file 33 manages the changing state information contained in the changed medical information display information. The changing state information is managed for every medical information display information and shows one of uncorrected, addition, deletion, correction/deletion and correction/addition states. Thus, the relation is managed between the unchanged information and the changed information.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an antibacterial agent which is safe even when habitually used and is excellent in an antibacterial effect, and an antibacterial composition containing the antibacterial agent.  &lt;P&gt;SOLUTION: The antibacterial agent comprises amorphaquinone or contains amorphaquinone as an active ingredient. The antibacterial agent is applicable to cosmetics including quasi-drugs, drugs, food products, or the like. The antibacterial composition contains the antibacterial agent or amorphaquinone. Examples of the composition are cosmetics including quasi-drugs, drugs, or foods.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI